DOCSLIB.ORG

Official Proceedings

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Official Proceedings Scientific Session Awards Abstracts presented at the Society’s annual meeting will be considered for the following awards: The George Peters Award recognizes the best presentation by a breast fellow. In addition to a plaque, the winner receives $1,000. The winner is selected by the Society’s Publications Committee. The award was established in 2004 by the Society to honor Dr. George N. Peters, who was instrumental in bringing together the Susan G. Komen Breast Cancer Foundation, The American Society of Breast Surgeons, the American Society of Breast Disease, and the Society of Surgical Oncology to develop educational objectives for breast fellowships. The educational objectives were first used to award Komen Interdisciplinary Breast Fellowships. Subsequently the curriculum was used for the breast fellowship credentialing process that has led to the development of a nationwide matching program for breast fellowships. The Scientific Presentation Award recognizes an outstanding presentation by a resident, fellow, or trainee. The winner of this award is also determined by the Publications Committee. In addition to a plaque, the winner receives $500. All presenters are eligible for the Scientific Impact Award. The recipient of the award, selected by audience vote, is honored with a plaque. All awards are supported by The American Society of Breast Surgeons Foundation. 2 Publications Committee Chair Judy C. Boughey, MD Members Charles Balch, MD Sarah Blair, MD Katherina Zabicki Calvillo, MD Suzanne Brooks Coopey, MD Emilia Diego, MD Jill Dietz, MD Mahmoud El-Tamer, MD Mehra Golshan, MD E. Shelley Hwang, MD Susan Kesmodel, MD Brigid Killelea, MD Michael Koretz, MD Henry Kuerer, MD, PhD Swati A. Kulkarni, MD Holly Mason, MD Tracy-Ann Moo, MD Roshni Rao, MD Miraj Shah-Khan, MD Elizabeth Shaughnessy, MD Jennifer Steiman, MD Stephanie Valente, DO Richard White, MD Jan H. Wong, MD Katharine A. Yao, MD 3 This supplement was not sponsored by outside commercial interests. It was funded entirely by the publisher. 4 Contents Scientific Presentations 2018 ........................................................................................................ 18 Scientific Oral Presentations I .................................................................................................... 18 403081 - Lymph node status does not predict tumor biology ............................................. 18 403956 - Local recurrence rates after breast-conserving therapy in patients receiving modern era therapy .............................................................................................................. 19 403265 - Chronic pain after breast surgery: A prospective observational trial ................... 21 404340 - HBOC patients who do not meet Medicare criteria for genetic testing have similar rates of clinically actionable findings as those who do meet criteria .................................. 22 402910 - Are genetic testing guidelines still relevant? ......................................................... 23 Scientific Oral Presentations II ................................................................................................... 25 403418 - Axillary nodal evaluation in elderly breast cancer patients: Potential effects on treatment decisions and survival .......................................................................................... 25 403819 - The feasibility of breast-conserving surgery for multiple ipsilateral breast cancer: An initial report from ACOSOG Z11102 Alliance trial ........................................................... 27 404366 - The impact of post-mastectomy chest wall radiation on prepectoral implant- based breast reconstruction ................................................................................................. 28 404138 - Long-term patient satisfaction after nipple-sparing mastectomy and conventional mastectomy with reconstruction does not differ significantly ............................................ 29 404290 - Is age trumping genetic profiling in clinical practice? Relationship of chemotherapy recommendation and Oncotype DX recurrence score in patients <50 versus >50 and trends over time ..................................................................................................... 32 Quickshot Presentations ............................................................................................................. 34 402997 - Oncotype DX® recurrence score as a predictor of response to neoadjuvant chemotherapy ....................................................................................................................... 34 404086 - Association of 21-gene recurrence score results with surgical intervention received after neoadjuvant hormonal therapy: Secondary endpoints of the TransNEOS validation study ..................................................................................................................... 35 403780 - Utility of expedited hereditary cancer testing in surgical management of newly diagnosed breast cancer patients ......................................................................................... 36 403256 - Predicting non-sentinel lymph node metastases in patients with a positive sentinel lymph node after neoadjuvant chemotherapy ....................................................... 39 404038 - Prospective evaluation of quality of life for patients with breast cancer treated with breast-conserving surgery, mastectomy alone, and mastectomy with immediate breast reconstruction ........................................................................................................... 41 404025 - No change in contralateral prophylactic mastectomy rates after implementation of a patient educational handout based on the 2016 ASBrS consensus statement: An ongoing quality improvement initiative ............................................................................... 42 404031 - Multidisciplinary margin assessment reduces number of positive margins ......... 44 403777 - Litigation for breast cancer care: Delay in diagnosis continues to top the chart . 45 404018 - Reducing breast cancer-related lymphedema (BCRL) through prospective surveillance monitoring using bioimpedance spectroscopy (BIS) and patient-directed self- interventions ......................................................................................................................... 47 5 Top 12 .......................................................................................................................................... 48 403787 - Can PREDICT and BOADICEA scores help identify patients that would benefit from risk-reducing mastectomy? .................................................................................................. 48 404284 - Multi-gene panel testing increases yield of surgically actionable results among breast cancer patients .......................................................................................................... 50 403820 - Impact of screening mammography interval on stage and treatment in women diagnosed with breast cancer ............................................................................................... 51 398829 - A potential role for peripheral natural killer (NK) cell activity induced by pre- operative chemotherapy in breast cancer patients ............................................................. 52 403876 - Phase II open-label trial investigating percutaneous laser ablation for treatment of early-stage breast cancer: MRI, pathology, and outcome correlations ........................... 53 403423 - 'Driving' rates down: A population-based evaluation of travel time to radiation center on the use of mastectomy for breast cancer ............................................................ 54 404003 - Impact of breast reconstruction on time to definitive surgical treatment, adjuvant therapy, and breast cancer outcomes .................................................................................. 57 403817 - Evaluation of Oncotype DX as a predictor of nodal burden in clinically node negative breast cancer patients............................................................................................ 59 403976 - Deep learning through convolutional neural networks using a breast MRI tumor dataset can predict axillary neoadjuvant chemotherapy response ..................................... 60 404081 - Extent of axillary surgery in women with Stage IV breast cancer ......................... 61 403837 - Low mutant allele tumor heterogeneity (MATH) is associated with activation of the immune response and improved survival of breast cancer patients ............................. 62 404183 - High androgen receptor expression tumors have worse overall survival in ER- positive breast cancer ........................................................................................................... 63 Poster Session I ............................................................................................................................ 65 Benign ....................................................................................................................................... 65 402780 - Idiopathic granulomatous mastitis - A 10-year review on a region-wide, multi- center database .................................................................................................................... 65 404085 - Re-evaluating if observation continues to be the management of idiopathic
Load more

Recommended publications
  • Understanding Hereditary Breast & Ovarian Cancer
    Understanding Hereditary Breast & Ovarian Cancer – the BRCA genes understanding hereditary breast & ovarian cancer – the brca genes 3 Contents Introduction Introduction ___________________________________________________________ 3 The purpose of this booklet is to review the information How are cancer & genes related? _________________________________________ 4 about hereditary breast and ovarian cancer as discussed in What is known about hereditary cancer? ___________________________________ 5 a genetic counselling session. You may also wish to use this Is my family at risk? _____________________________________________________ 6 booklet to help you share information with other family members. The BRCA1 and BRCA2 genes _____________________________________________ 7 What happens if there is a mutation in a BRCA gene? _________________________ 7 This booklet was prepared by staff of the Hereditary Cancer What happens if a person inherits a BRCA gene mutation? ____________________ 8 Program, based on information that was current at the time What are the risks for the children of a BRCA gene mutation carrier? ___________ 9 of printing. What is the risk of cancer for a BRCA gene mutation carrier? __________________10 What is genetic testing? _________________________________________________ 11 Words that may be new to you are highlighted and are Who can have BRCA genetic testing? ______________________________________ 11 defined in the Glossary on page 28. How is BRCA genetic testing done? ________________________________________12 Results
    [Show full text]
  • 30Th Annual Meeting “Rapid Evolution in the Healthcare Ecosystem: Become Frontiers”
    2020 FINAL PROGRAM North American Skull Base Society 30th Annual Meeting “Rapid Evolution in the Healthcare Ecosystem: Become Frontiers” February 7-9, 2020 La Cantera Resort & Spa, San Antonio, TX Pre-Meeting Dissection Course: February 5-6, 2020 PRESIDENT: Ricardo Carrau, MD, MBA PROGRAM CHAIRS: Adam Zanation, MD & Daniel Prevedello, MD PRE-MEETING COURSE CHAIRS: Paul Gardner, MD & Arturo Solares, MD SCIENTIFIC PROGRAM COMMITTEE: Ricardo Carrau, MD, MBA, President, Adam Zanation, MD, MBA, Program Co-Chair, Daniel Prevedello, MD, Program Co-Chair, Paul Gardner, MD, Arturo Solares, MD, FACS, James Evans, MD, FACS, FAANS, Shaan Raza, MD, Brian Thorp, MD, Deanna Sasaki-Adams, MD, Chris Rassekh, MD, Christine Klatt-Cromwell, MD, Tonya Stefko, MD, Moises Arriaga, MD, Jamie Van Gompel, MD, Kibwei McKinney, MD, Derrick Lin, MD, FACS, Carlos Pinheiro-Neto, MD, PhD Dear friends and colleagues, Welcome to the 30th Annual Meeting of the North American Skull Base Society! This event will be held at La Cantera Resort in San Antonio, Texas; February 7-9, 2020 with a pre-meeting hands-on dissection course February 5-6, 2020. La Cantera is a beautiful resort, full of family- oriented amenities, located just 20 minutes from San Antonio’s downtown, The Alamo historical site and the world renowned Riverwalk. The meeting theme, Rapid Evolution in the Healthcare Ecosystem: Ricardo Carrau, MD, MBA Becoming Frontiers, will present the opportunity to discuss technological, technical, societal and economic changes affecting the way we deliver care to our patients and how our frontier horizon changes faster than our ability to adapt to these changes (“becoming frontiers”).
    [Show full text]
  • Unresolved, Atraumatic Breast Hematoma: Post-Irradiation Or Secondary Breast Angiosarcoma
    Breast Disease 33 (2011/2012) 139142 139 DOI 10.3233/BD-2012-0331 IOS Press Case Report Unresolved, atraumatic breast hematoma: Post-irradiation or secondary breast angiosarcoma Glenn Hanna, Samuel J. Lin, Michael D. Wertheimer and Ranjna Sharma Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Department of Plastic and Reconstructive Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Abstract. Post-irradiation or secondary angiosarcoma of the breast was rst described in the 1980s in patients treated with breast conserving therapy for cancer. The primary management of radiation-induced breast angiosarcoma has focused on surgical resection with an emphasis on achieving negative tumor margins. While surgery remains a key component of treatment, novel therapeutic approaches have surfaced. Despite such advances in treatment, prognosis remains poor. Keywords: Breast cancer, breast conservation therapy, secondary angiosarcoma 1. Clinical scenario amination showed the left breast to be larger than the right, with a 10 15cm areaofa clinicalhematomalo- A 64-year-old post-menopausal Caucasian female cated in the superior and inferior outer quadrants. The presented to our institution with a seven month history overlying skin was hemorrhagic, necrotic and had in- of an unresolved left breast hematoma. Of note, she durated features with areas of active bleeding. Initially, had a history of left breast inltrating ductal carcinoma no discrete underlying mass was identied on physical that was Her-2/Neu negative with estrogen and proges- examination. Areas of peau de orange surrounded the terone receptor positivity seven years prior. She had lesion. She had no palpable lymphadenopathy.
    [Show full text]
  • Surgical Approach to the Treatment of Gynecomastia According to Its Classification
    ARTIGO ORIGINAL Abordagem cirúrgica para o tratamentoVendraminFranco da T ginecomastia FSet al.et al. conforme sua classificação Abordagem cirúrgica para o tratamento da ginecomastia conforme sua classificação Surgical approach to the treatment of gynecomastia according to its classification MÁRIO MÚCIO MAIA DE RESUMO MEDEIROS1 Introdução: A ginecomastia é a proliferação benigna mais comum do tecido glandular da mama masculina, causada pela alteração do equilíbrio entre as concentrações de estrógeno e andrógeno. Na maioria dos casos, o principal tratamento é a cirurgia. O objetivo deste tra- balho foi demonstrar a aplicabilidade das técnicas cirúrgicas consagradas para a correção da ginecomastia, de acordo com a classificação de Simon, e apresentar uma nova contribuição. Método: Este trabalho foi realizado no período de março de 2009 a março de 2011, sendo incluídos 32 pacientes do sexo masculino, com idades entre 13 anos e 45 anos. A escolha da incisão foi relacionada à necessidade ou não de ressecção de pele. Foram utilizadas quatro técnicas da literatura e uma modificação da técnica por incisão circular com prolongamentos inferior, superior, lateral e medial, quando havia excesso de pele também no polo inferior da mama. Resultados: A principal causa da ginecomastia identificada entre os pacientes foi idiopática, seguida pela obesidade e pelo uso de esteroides anabolizantes. Conclusões: A técnica mais utilizada foi a incisão periareolar inferior proposta por Webster, quando não houve necessidade de ressecção de pele. Na presença de excesso de pele, a técnica escolhi- da variou de acordo com a quantidade do tecido a ser ressecado. A nova técnica proposta permitiu maior remoção do tecido dermocutâneo glandular e gorduroso da mama, quando comparada às demais técnicas utilizadas na experiência do cirurgião.
    [Show full text]
  • Massachusetts Breastfeeding Resource Guide
    Massachusetts Breastfeeding Resource Guide 2008 Edition © 254 Conant Road Weston, MA 02493 781 893-3553 Fax 781 893-8608 www.massbfc.org Massachusetts Breastfeeding Coalition Leadership Chair Board Member Melissa Bartick, MD, MS Lauren Hanley, MD Treasurer Board Member Gwen MacCaughey Marsha Walker, RN, IBCLC NABA, Lactation Associates Clerk Xena Grossman, RD, MPH Board Member Anne Merewood, MPH, IBCLC Board Member Lucia Jenkins, RN, IBCLC La Leche League of MA RI VT 10th edition (2008) Compiled and edited by Rachel Colchamiro, MPH, RD, LDN, CLC and Jan Peabody Cover artwork courtesy of Peter Kuper Funding for the printing and distribution of the Massachusetts Breastfeeding Resource Guide is provided by the Massachusetts Department of Public Health-Bureau of Family and Community Health, Nutrition Division. Permission is granted to photocopy this guide except for the three reprinted articles from the American Academy of Pediatrics and two articles from the American Academy of Family Physicians. Adapted from the Philadelphia Breastfeeding Resource Handbook. hhhhhhhhhhhhhhhhhhhhTable of Contents Organizational statements on breastfeeding…………………………………………………………….2 Breastfeeding and the Use of Human Milk, American Academy of Pediatrics…………………….6 Breastfeeding Position Paper, American Academy of Family Physicians……………………...…19 Breastfeeding initiatives………………………...……………………………………………………...…37 Breastfeeding support and services…………………………………………...………………...…....…39 La Leche League International leaders………….…………………………………………………...….40 Lactation consultants………………………………………………………………………………….…..44
    [Show full text]
  • Benign Breast Diseases1
    BENIGN BREAST DISEASES PROFFESOR.S.FLORET NORMAL STRUCTURE DEVELOPMENTAL/CONGENITAL • Polythelia • Polymastia • Athelia • Amastia ‐ poland syndrome • Nipple inversion • Nipple retraction • NON‐BREAST DISORDERS • Tietze disease • Sebaceous cyst & other skin disorders. • Monder’s disease BENIGN DISEASE OF BREAST • Fibroadenoma • Fibroadenosis‐ ANDI • Duct ectasia • Periductal papilloma • Infective conditions‐ Mastitis ‐ Breast abscess ‐ Antibioma ‐ Retromammary abscess Trauma –fat necrosis. NIPPLE INVERSION • Congenital abnormality • 20% of women • Bilateral • Creates problem during breast feeding • Cosmetic surgery does not yield normal protuberant nipple. NIPPLE INVERSION NIPPLE RETRACTION • Nipple retraction is a secondary phenomenon due to • Duct ectasia‐ bilateral nipple retarction. • Past surgery • Carcinoma‐ short history,unilateral,palpable mass. NIPPLE RETRACTION ABERRATIONS OF NORMAL DEVELOPMENT AND INVOLUTION (ANDI) • Breast : Physiological dynamic structure. ‐ changes seen throught the life. • They are ‐ developmental & involutional ‐ cyclical & associated with pregnancy and lactation. • The above changes are described under ANDI. PATHOLOGY • The five basic pathological features are: • Cyst formation • Adenosis:increase in glandular issue • Fibrosis • Epitheliosis:proliferation of epithelium lining the ducts & acini. • Papillomatosis:formation of papillomas due to extensive epithelial hyperplasia. ANDI & CARCINOMA • NO RISK: • Mild hyperplasia • Duct ectasia. • SLIGHT INCREASED RISK(1.5‐2TIMES): • Moderate hyperplasia • Papilloma
    [Show full text]
  • Breastfeeding After Breast Surgery-V3-Formatted
    Breastfeeding After Breast and Nipple Surgeries: A Guide for Healthcare Professionals By Diana West, BA, IBCLC, RLC PURPOSE A satisfying breastfeeding relationship is not precluded by insufficient milk production. When measures are taken to protect the milk supply that exists, minimize supplementation, The purpose of this guide is to provide the healthcare and increase milk production when possible, a mother with professional with an understanding of breast and nipple compromised milk production can have a satisfying surgeries and their effects upon lactation and the breastfeeding relationship with her baby. breastfeeding relationship. The effect of breast and nipple surgery upon lactation functionality and breastfeeding dynamics varies according to the type of surgery performed. This guide has delineated discussion of breastfeeding after PREDICTING LACTATION breast and nipple surgeries according to the three broad CAPABILITY AFTER BREAST AND categories: diagnostic, ablative, and therapeutic breast procedures, cosmetic breast surgeries, and nipple surgeries. NIPPLE SURGERIES The reasons, motivations, issues, concerns, stresses, and physical and psychological results share some The aspect of breast and nipple surgeries that is most likely to commonalities, but are largely unique to the type of surgery affect lactation is the surgical treatment of the areola and performed. For this reason, each type of surgery and its nipple. The location, orientation, and length of the incision effect upon lactation will be discussed independently. directly affect lactation capability by severing the parenchyma Methods to assess milk production and an overview of and innervation to the nipple/areolar complex. An incision feeding options to maximize milk production when near or on the areola, particularly in the lower, outer quadrant supplementation is necessary are presented.
    [Show full text]
  • The Thoracic Radiologist's Guide to the Breast
    The Thoracic Radiologist’s Guide to the Breast Gurpriya Gupta MD, Stacy Ries, DO, Jillian Krauss MD, Sayf Al-Katib MD, and Michael Farah MD 1: Beaumont Health System, Royal Oak MI Learning Objectives T o recognize normal CT appearance of breast tissue as CT may often provide the first images of the breast ⦿ To identify CT cross-sectional imaging appearance of benign and malignant breast processes in females and males ⦿ To become familiar with expected cross-sectional imaging appearance of the post-operative breast and recognize post-operative complications ⦿ To discuss the potential advantages of CT evaluation of the breast and encourage accurate description of findings for more valuable reporting ⦿ DisclosureDisclosures The authors of this educational exhibit have no significant financial disclosures to make. Introduction • Increased utilization of CT imaging has led to increased detection of incidental breast lesions • CT may be the first evaluation of the breast • Breast findings may easily be missed or not appropriately managed • 2003 study evaluating MDCT perform on 149 women with 173 breast lesions (Inoue et al) • Features predictive of malignancy: irregular margins, irregular shape, and rim enhancement • 2010 study with 78 incidental breast lesions on CT (Moyle et al) • Best morphological predictors of malignancy: spiculation and irregularity • Calcification patterns were found to be “diagnostically unhelpful” • Limited literature regarding imaging features for benign breast findings on CT. • Therefore, in the absence of long-term
    [Show full text]
  • Breast Uplift (Mastopexy) Procedure Aim and Information
    Breast Uplift (Mastopexy) Procedure Aim and Information Mastopexy (Breast Uplift) The breast is made up of fat and glandular tissue covered with skin. Breasts may change with variable influences from hormones, weight change, pregnancy, and gravitational effects on the breast tissue. Firm breasts often have more glandular tissue and a tighter skin envelope. Breasts become softer with age because the glandular tissue gradually makes way for fatty tissue and the skin also becomes less firm. Age, gravity, weight loss and pregnancy may also influence the shape of the breasts causing ptosis (sagging). Sagging often involves loss of tissue in the upper part of the breasts, loss of the round shape of the breast to a more tubular shape and a downward migration of the nipple and areola (dark area around the nipple). A mastopexy (breast uplift) may be performed to correct sagging changes in the breast by any one or all of the following methods: 1. Elevating the nipple and areola 2. Increasing projection of the breast 3. Creating a more pleasing shape to the breast Mastopexy is an elective surgical operation and it typifies the trade-offs involved in plastic surgery. The breast is nearly always improved in shape, but at the cost of scars on the breast itself. A number of different types of breast uplift operations are available to correct various degrees of sagginess. Small degrees of sagginess can be corrected with a breast enlargement (augmentation) only if an increase in breast size is desirable, or with a scar just around the nipple with or without augmentation.
    [Show full text]
  • R2P2 Resident Radpath .Pptx
    Clues You Can Use: Core Breast Breast Imaging Division March 2018 BI-RADS® Assessment Categories o Assessments are divided into incomplete Category 0 and final assessment categories Categories 1-6 o Overall assessment based on the most worrisome finding or the need for immediate additional evaluation o Screening mammograms may be assigned Category 0,1,2 BI-RADS® Assessment Categories o BI-RADS® Category 0: INCOMPLETE - NEED ADDITIONAL IMAGING EVALUATION AND/OR PRIOR MAMMOGRAMS FOR COMPARISON o BI-RADS® Category 1: NEGATIVE o BI-RADS® Category 2: BENIGN o BI-RADS® Category 3: PROBABLY BENIGN o BI-RADS® Category 4: SUSPICIOUS o BI-RADS® Category 5: HIGHLY SUGGESTIVE OF MALIGNANCY o BI-RADS® Category 6: KNOWN BIOPSY-PROVEN MALIGNANCY Management Recommendations o Management recommendations on a per Assessment basis o Wording emphasizes recall, routine mammography screening, tissue diagnosis, surgical excision o Management recommended wording for tissue diagnosis is: “Biopsy should be performed in the absence of clinical contraindications.” o Management recommended wording for BI-RADS® 6 is : “Surgical excision when clinically appropriate.” o Category 0: INCOMPLETE - NEED ADDITIONAL IMAGING EVALUATION AND/OR PRIOR MAMMOGRAMS FOR COMPARISON Recall for additional imaging and/or comparison with prior examinations o Category 1: NEGATIVE Routine mammography screening o Category 2: BENIGN Routine mammography screening o Category 3: PROBABLY BENIGN Short interval 6 month follow-up OR continued surveillance o Category 4: SUSPICIOUS ABNORMALITY Biopsy
    [Show full text]
  • Phd Thesis Summary
    University of Medicine and Pharmacy of Craiova DOCTORAL SCHOOL PhD Thesis BREAST RECONSTRUCTION AFTER SURGERY FOR BREAST HIPERTROPHY AND BENIGN TUMORS Summary Ph.D. SUPERVISOR: Prof. univ. dr. Mihai Brăila Ph.D. CANDIDATE: Radu Claudiu Gabriel CRAIOVA 2013 INTRODUCTION According to statistics, only in the United States in 2012 over 14 million cosmetic surgery of the breasts were made, but only about 3% of these were for surgical breast reconstruction after mastectomy as an interventional oncology treatment, although about 300,000 women are diagnosed each year with mammary tumors and most of them suffer breast surgery that can vary from partial, segmental or total removal of the breast. This creates a major gap between the number of surgeons able to successfully carry out such intervention and the number of patients who would require them, making obvious the need to increase the number of professionals that are able to perform breast reconstruction after mastectomy, especially the aesthetic mastectomy in people diagnosed with breast hypertrophy. Based on medical literature data, in this study we aimed to elucidate, using specific research methods, the impact of clinical and psychological intervention of breast reconstruction in patients suffering from breast hypertrophy and benign tumors. We hope that our study will shade some light on the need of brest reconstruction, its impact on specific pathology (mammary hypertrophy and benign tumors) and to contribut in improving breast reconstruction techniques that can help to avoid any complication that may arise. CHAPTER I Functional anatomy of the mammary gland Adult female mammary gland is located on both side of the anterior chest having it's base stretching from about the second to the sixth rib.
    [Show full text]
  • BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives
    cancers Review BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives Eleonora Molinaro, Kalliopi Andrikou, Andrea Casadei-Gardini * and Giulia Rovesti Department of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 41121 Modena, Italy; [email protected] (E.M.); [email protected] (K.A.); [email protected] (G.R.) * Correspondence: [email protected] Received: 10 October 2020; Accepted: 11 November 2020; Published: 12 November 2020 Simple Summary: BRCA gene mutations are progressively gaining more attention in the context of gastrointestinal malignancies, especially in pancreatic cancer where their identification can have both therapeutic and surveillance relevance. Abstract: A strong association between pancreatic cancer and BRCA1 and BRCA2 mutations is documented. Based on promising results of breast and ovarian cancers, several clinical trials with poly (ADP-ribose) polymerase inhibitors (PARPi) are ongoing for gastrointestinal (GI) malignancies, especially for pancreatic cancer. Indeed, the POLO trial results provide promising and awaited changes for the pancreatic cancer therapeutic landscape. Contrariwise, for other gastrointestinal tumors, the rationale is currently only alleged. The role of BRCA mutation in gastrointestinal cancers is the subject of this review. In particular, we aim to provide the latest updates about novel therapeutic strategies that, exploiting DNA repair defects, promise to shape the future therapeutic scenario of GI cancers. Keywords: BRCA1; BRCA2; gastrointestinal cancers; HRD; pancreatic cancer; Olaparib; PARP inhibitors; surveillance 1. Introduction BRCA1 and BRCA2 are famous tumor susceptibility genes. They encode for proteins playing a crucial role in the correct repair of damaged DNA. Indeed, these genes are key components of the homologous recombination (HR) pathway [1].
    [Show full text]